Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase

Cancer Gene Therapy volume 10, pages 23–29 (2003)Cite this article

Abstract

The selective expression of Escherichia coli purine nucleoside phosphorylase (PNP) in solid tumors has been successfully used to activate two purine nucleoside analogs [9-(2-deoxy-β-D-ribofuranosyl)-6-methylpurine (MeP-dR) and 9-β-D-arabinofuranosyl-2-fluoroadenine (F-araA)] resulting in lasting tumor regressions and cures. E. coli PNP also cleaves 2-fluoro-2′-deoxyadenosine (F-dAdo) to 2-F-adenine, which is the toxic purine analog liberated from F-araA that has high bystander activity and is active against nonproliferating tumor cells. As F-dAdo is 3000 times better than F-araA as a substrate for E. coli PNP, we have evaluated its antitumor activity against D54 gliomas that express E. coli PNP and have characterized its in vivo metabolism in order to better understand its mechanism of action with respect to the other two agents. Like MeP-dR and F-araA-5′-monophosphate (F-araAMP, a prodrug of F-araA), treatment of mice bearing D54 tumors that express E. coli PNP with F-dAdo resulted in excellent antitumor activity. Although F-dAdo was as active as MeP-dR and better than F-araAMP, it was not dramatically better than either compound because of its short plasma half-life and the limited activation of F-adenine to toxic metabolites. Regardless, these results indicated that F-dAdo was also an excellent prodrug for use with gene vectors that deliver E. coli PNP to tumor cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr & Parker WB . Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Ther. 1994; 1: 233–238.

    CAS  PubMed  Google Scholar 

  2. Parker WB, King SA & Allan PW, et al. In vivo gene therapy of cancer using E. coli purine nucleoside phosphorylase. Hum Gene Ther. 1997; 8: 1637–1644.

    Article  CAS  Google Scholar 

  3. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB & Sorscher EJ . In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Ther. 2000; 7: 1738–1743.

    Article  CAS  Google Scholar 

  4. Mohr L, Shankara S & Yoon SK, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology. 2000; 31: 606–614.

    Article  CAS  Google Scholar 

  5. Park BJ, Brown CK & Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999; 10: 889–898.

    Article  CAS  Google Scholar 

  6. Puhlmann M, Gnant M, Brown CK, Alexander HR & Bartlett DL . Thymidine kinase–deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther. 1999; 10: 649–657.

    Article  CAS  Google Scholar 

  7. Martiniello-Wilks R, Garcia-Aragon J & Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998; 9: 1617–1626.

    Article  CAS  Google Scholar 

  8. Lockett LJ, Molloy PL, Russell PJ & Both GW . Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res. 1997; 3: 2075–2080.

    CAS  PubMed  Google Scholar 

  9. Nestler U, Heinkelein M & Lucke M, et al. Foamy virus vectors for suicide gene therapy. Gene Ther. 1997; 4: 1270–1277.

    Article  CAS  Google Scholar 

  10. Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW & Vogelstein B . Converting cancer genes into killer genes. Proc Natl Acad Sci USA. 1996; 93: 4192–4196.

    Article  CAS  Google Scholar 

  11. Hughes BW, Wells AH & Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 1995; 55: 3339–3345.

    CAS  PubMed  Google Scholar 

  12. Hughes BW, King SA, Allan PW, Parker WB & Sorscher EJ . Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J Biol Chem. 1998; 273: 2322–2328.

    Article  CAS  Google Scholar 

  13. Parker WB, Allan PW & Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol. 1998; 55: 1673–1681.

    Article  CAS  Google Scholar 

  14. Noker PE, Duncan GF, El Dareer SM & Hill DL . Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat Rep. 1983; 67: 445–456.

    CAS  PubMed  Google Scholar 

  15. Parker WB, Bapat AR, Shen JX, Townsend AJ & Cheng YC . Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988; 34: 485–491.

    CAS  PubMed  Google Scholar 

  16. Montgomery JA . Has the well gone dry?. Cancer Res. 1982; 42: 3911–3917.

    CAS  PubMed  Google Scholar 

  17. Parker WB, Waud WR, Allan PW, Sorsher EJ, Hassan AE & Secrist JA III . In vivo anti-tumor activity of 2-fluoro-2′-deoxyadenosine (F-dAdo) against human tumors that express the E. coli purine nucleoside phosphorylase gene. Proc Am Assoc Cancer Res. 2001; 92, (Abstract 3503)

  18. Dykes DJ, Abbott BJ & Mayo JG, et al. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel, Karger. 1992; 42: 1–22.

    Google Scholar 

  19. Montgomery JA & Hewson K . Analogs of 6-methyl-9-β-D-ribofuranosylpurine. J Med Chem. 1968; 11: 48–52.

    Article  CAS  Google Scholar 

  20. Hassan AEA, Shortnacy-Fowler AT, Montgomery JA & Secrist JA III . A convenient synthesis of 2′-deoxy-2-fluoroadenosine; a potential prodrug for suicide gene therapy. Nucleosides Nucleotides Nucleic Acids. 2000; 19: 559–565.

    Article  CAS  Google Scholar 

  21. Plunkett W, Huang P & Gandhi V . Metabolism and action of fludarabine phosphate. Semin Oncol. 1990; 17: 3–17.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Cancer Institute Grant CA67763.

Author information

Authors and Affiliations

  1. Southern Research Institute, Birmingham, 35205, Alabama, USA

    William B Parker, Paula W Allan, Abdalla E A Hassan, John A Secrist III & William R Waud

  2. University of Alabama at Birmingham, Birmingham, 35294, Alabama, USA

    Eric J Sorscher

Authors
  1. William B Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula W Allan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdalla E A Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John A Secrist III
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric J Sorscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William R Waud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William B Parker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, W., Allan, P., Hassan, A. et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 10, 23–29 (2003). https://doi.org/10.1038/sj.cgt.7700520

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700520

Keywords

This article is cited by

Search

Advanced search

Quick links